Trial updateRetina
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Completed. Phase 2. Registered enrolment: 300. Aviceda Therapeutics, Inc.
Why it matters
Track this study through NCT05839041. No results are posted in this registry record.
The study at a glance
- Registry status
- Completed
- Phase
- Phase 2
- Registered enrolment
- 300
- Results posted
- No
- Sponsor
- Aviceda Therapeutics, Inc.
Keep in mind
Registry information describes the study; recruitment status alone does not establish efficacy or safety.